| Document |
Document Title |
|
WO/2018/102006A1 |
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of indoleamine-2,3-dioxygenase (IDO) activity, and methods of treating IDO-related disorders.
|
|
WO/2018/100560A1 |
The present invention concerns Au and Cu-based mononuclear coordination compounds, drug formulations thereof, the relating synthesis and encapsulation method in macromolecules or supramolecular aggregates or nanostructures, as well as th...
|
|
WO/2018/100515A1 |
The invention relates to novel ruthenium complexes of formula (9). The invention also relates to the method for preparation of novel metal complexes of formula (9) and their use in olefin metathesis reactions.
|
|
WO/2018/095488A1 |
The invention relates to sulfobetaine compounds, a process for synthesizing same, and the uses of sulfobetaine compounds for synthesizing antimicrobial materials, antistatic materials, antifouling materials, printing inks, surface-active...
|
|
WO/2018/095422A1 |
Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a bio...
|
|
WO/2018/091153A1 |
The present invention relates to novel substituted N-(3-fluoropropyl)-pyrrolidine compounds of formula (l-A): wherein R1 and R2 represent independently a hydrogen atom or a deuterium atom; A represents an oxygen or nitrogen atom; and SER...
|
|
WO/2018/091222A1 |
Compositions comprising a lactam. Pharmaceutical compositions comprising such lactams for use in methods of treatment.
|
|
WO/2018/090787A1 |
Provided herein are the crystalline form of chlorfenapyr of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods, using the crystal to prepare stable agrochemical formulation, and t...
|
|
WO/2018/094335A1 |
The present invention relates to novel small molecule modulators of Nav1.6 channels of the general formulae (I), (II), (III) and (IV), and the uses thereof.
|
|
WO/2018/091221A1 |
Compositions comprising a lactam. Pharmaceutical compositions comprising such lactams for use in methods of treatment.
|
|
WO/2018/089402A1 |
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...
|
|
WO/2018/087685A1 |
Adducts are described formed between pyrrole derivatives of formula (I) an carbon allotropes in which the carbon is sp2 hybridized, such as for example carbon nanotubes, graphene or nanographites, carbon black. The pyrrole derivatives be...
|
|
WO/2018/086530A1 |
Provided is a series of sulfonamide compounds as a cccDNA inhibitor. Particularly, the present invention relates to a compound represented by formula (I) as a cccDNA inhibitor or a pharmaceutically acceptable salt thereof.
|
|
WO/2018/087019A1 |
The invention relates to a method for producing amide bonds, particularly peptide bonds, with the aid of new amide coupling reagents containing an anion of formula (I); the invention also relates to these new reagents and to the producti...
|
|
WO/2018/087688A1 |
Adducts are described, obtainable from the reaction product of a secondary amine and a diketone, with carbon allotropes in which the carbon is sp2 hybridized, such as graphene, graphite, fullerene, carbon nanotubes and the like, and an i...
|
|
WO/2018/089406A1 |
There are described RORɣ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical composi...
|
|
WO/2018/086507A1 |
The invention discloses a naphthalene sulfonamide type compound, a preparation method thereof and an application thereof for regulating plant growth activity. A general formula of a structure of the naphthalene sulfonamide type compound ...
|
|
WO/2018/081814A1 |
The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.
|
|
WO/2018/080269A1 |
The present invention relates to novel functional derivatives of alanine and proline amino acids. The compounds of the present invention were confirmed to have a very superior antifungal or fungicidal effect. In addition, the compounds o...
|
|
WO/2018/076784A1 |
A crystalline form of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide is disclosed. The crystalline form has a diffraction peak when a diffraction angle, 2θ, is 16.66±0.2°, 17.54±0.2°, 21±0.2°, 22.16±0.2°, or 30.96±0.2°. The crysta...
|
|
WO/2018/072739A1 |
Disclosed is a method for comprehensive recycling of a by-product slurry during polyphenylene sulfide (PPS) production. Na2CO3 is added to the slurry, and then a solvent NMP is recovered by distillation and drying, then an acid solution ...
|
|
WO/2018/072689A1 |
The present invention provides a stachydrine derivative, a preparation method therefor, and applications thereof in the preparation of drugs for treating cardiovascular and cerebrovascular diseases. The stachydrine derivative is a compon...
|
|
WO/2018/074566A1 |
The present invention provides an efficient production method for industrial mass synthesis of a pyrrolidine compound represented by formula (I) or a salt thereof, the method comprising reacting a compound represented by formula (II) or ...
|
|
WO/2018/069732A1 |
This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compo...
|
|
WO/2018/071741A1 |
The invention provides sulfoxyalkyl organonitro and related compounds, compositions containing such compounds, and methods for using such compounds and compositions to treat medical disorders, such as a neurodegenerative disorder, autoim...
|
|
WO/2018/071893A1 |
Methods of treating neuropathic pain in spinal cord injured individuals by administering levetiracetam or brivaracetam are described.
|
|
WO/2018/065962A1 |
The invention discloses compounds of Formula (I), wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their produc...
|
|
WO/2018/065921A1 |
The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, ...
|
|
WO/2018/066646A1 |
The present invention addresses the problem of finding a novel medicine which has an excellent tryptophanase inhibitory effect, suppresses indoxyl sulfate production in blood to thereby prevent deterioration of renal function, and thus c...
|
|
WO/2018/065311A1 |
The present invention provides a composition comprising (A) a compound of formula (I): (I) wherein R is methyl or methoxy, R is hydrogen, methyl or ethoxy and A is a substituted heteroaryl group, or an N-oxide or salt form thereof, and (...
|
|
WO/2018/062197A1 |
Provided are: a liquid crystal alignment agent whereby a liquid crystal alignment film is obtained which has an excellent voltage holding ratio and fast relaxation of stored charge, and in which flickering is not prone to occur during dr...
|
|
WO/2018/059279A1 |
Disclosed is a method for synthesizing a novel chiral ligand, a metal chelate, a variety of non-natural amino acids, Maraviroc and a key intermediate thereof. In the invention, (R)-2-methyl proline is selected and used as a starting raw ...
|
|
WO/2018/062162A1 |
The purpose of the present invention is to provide a method for detecting a compound containing a formyl dehydropiperidine structure such as an acrolein-amine conjugate serving as an oxidative stress marker. More specifically, the method...
|
|
WO/2018/060689A1 |
The present invention relates to substituted-cyanopyrrolidines of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having ut...
|
|
WO/2018/055102A1 |
The present invention is directed to bioactive microcapsules and to the process for their production. More in particular, the present invention relates to the production of bioactive microcapsules, or porous microspheres by a water-in-oi...
|
|
WO/2018/055526A1 |
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.
|
|
WO/2018/055527A1 |
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.
|
|
WO/2018/053587A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2018/055524A1 |
The present invention relates to pyrrolidine sulfonamide analogs (I), pharmaceutical compositions containing them and their use as TRPV4 antagonists.
|
|
WO/2018/057134A1 |
The present invention relates to an unsaturated fluorinated ether or amine compound of formula (I) with low global warming potential and method of making the compound (I), where RH 1 is and RH 2 are independently selected from H or CH3, ...
|
|
WO/2018/054317A1 |
A method for recycling N-methylpyrrolidone (NMP) from a gas by utilizing a high boiling point solvent, comprising: spraying a high boiling point solvent into an absorption apparatus from the top of the absorption apparatus, pumping an NM...
|
|
WO/2018/050477A1 |
The present invention relates to relates to novel strigolactone derivatives of formula (I), to processes for preparing these derivatives including intermediate compounds, to seeds comprising these derivatives, to plant growth regulator o...
|
|
WO/2018/050631A1 |
The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preven...
|
|
WO/2018/049008A1 |
Disclosed are potent immuno-DASH inhibitors and their use in the treatment of cell proliferative diseases.
|
|
WO/2018/044817A1 |
The present invention relates to compositions and methods for the treatment of prostate cancer. The present invention relates to polyamides and prostate agents, for example, to inhibit an androgen receptor signaling axis, and the use of ...
|
|
WO/2018/044963A1 |
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...
|
|
WO/2018/042393A1 |
The present invention relates to a cost effective, novel and efficient process for the preparation of Brivaracetam which offers industrially viable, highly pure Brivaracetam in high yields and avoiding chiral resolutions by chromatograph...
|
|
WO/2018/042343A2 |
Compounds, specifically protease inhibitors, more specifically 3C and 3CL protease inhibitors, for the treatment of viral infections, and methods of preparing and using such compounds.
|
|
WO/2018/045084A1 |
The present invention is directed to methods of treating hematological cancers, such as acute myleiod leukemia, with tetracyclines, or a pharmaceutically acceptable salt thereof.
|
|
WO/2018/041639A1 |
The invention relates to a method for producing an N-acyl- or N-sulfonyl-α-aminonitrile, comprising the following steps: a) condensation of an N-acyl- or N-sulfonyl-α-aminoaldehyde with hydroxylamine to obtain an aldoxime, and b) dehyd...
|
